araag2/HINT huggingface dataset:
Clinical trial NCT01357395 (phase 2, status: completed)
Conditions: small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: amuvatinib
SMILES: S=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=C2C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female ≥ 18 of age at the time of consent and have histologically or
             cytologically confirmed SCLC

          2. Measurable SCLC per RECIST guideline that meets one of the following:

               -  Disease progression by RECIST at anytime during platinum-etoposide (PE)
                  chemotherapy;

               -  Relapse by RECIST within 90 days after completing PE chemotherapy;

               -  Stable disease by RECIST as best response after at least two (2) ≥ 21-day cycles
                  of PE chemotherapy. The assessment of stable disease should be made at least 2
                  weeks after the start of the second cycle

             Subjects who received another second-line therapy are eligible if they still fulfill
             any one of the above three conditions, and all other eligibility criteria

          3. Start treatment with the same last regimen (dose and schedule) of first-line PE
             chemotherapy that they progressed or relapsed on, including any dose reductions
             because of toxicity, prior to study entry

          4. ECOG performance status 0 to 2

          5. Adequate organ function

          6. Subjects with screening 12-lead ECG with measurable QTc interval of < 450 msec. If QTc
             ≥ 450 msec, then confirm the reading by evaluating the mean QTc interval of triplicate
             ECGs.

          7. Sign approved informed consent form

        Exclusion Criteria:

          1. Prior exposure to amuvatinib

          2. No longer eligible for first-line PE chemotherapy due to toxicity and the Investigator
             believes that the risk of retreating with the same PE chemotherapy regimen would
             outweigh the benefit

          3. Ongoing toxicity from prior treatment unless the toxicity has resolved, or in the
             opinion of the Investigator, is stable and does not compromise the safety of the
             subject

          4. Mixed SCLC and non-small cell lung cancer, or large cell lung cancer

          5. Untreated, unstable, or symptomatic brain metastasis

          6. Hypersensitivity to amuvatinib, excipients of amuvatinib, or any agent given in
             association with this trial

          7. A life-threatening illness, medical condition or organ system dysfunction which, in
             the Investigator's opinion, could compromise the subject's safety or interfere with
             study outcomes
Clinical trial NCT00005614 (phase 2, status: withdrawn)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Reason stopped: 
    no accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Metastatic breast cancer Measurable disease No progression after 3
        or more different forms of chemotherapy Hormone receptor positive breast cancer must be
        refractory to at least two forms of hormonal treatment (including antiestrogen, aromatase
        inhibitor, and/or progestin) unless there is life threatening metastases (e.g.,
        lymphangitic metastases to the lung or liver metastases) Must meet at least one of the
        following characteristics for frailty: ECOG 2-4 Dependence in at least one activity of
        daily living 85 and over History of three or more falls in the past 6 months Mild dementia
        (must be oriented in time, space, and location) Three or more comorbid conditions Hormone
        receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 65 and over Sex: Female Menopausal status: Not specified
        Performance status: See Disease Characteristics Life expectancy: Greater than 12 weeks
        Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Neutropenia or thrombocytopenia secondary to myelophthisis from breast cancer
        allowed Hepatic: Increased bilirubin allowed Renal: Renal insufficiency allowed
        Cardiovascular: Congestive heart failure allowed Other: No known allergy to gemcitabine

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: See Disease Characteristics Radiotherapy: At least 4
        weeks since prior radiotherapy to bony areas or CNS metastases Surgery: Not specified
        Other: Concurrent bisphosphonates allowed No concurrent participation in other
        investigational studies
Clinical trial NCT01516138 (phase 2, status: active, not recruiting)
Conditions: cardiac surgery, cardiopulmonary bypass
ICD codes: I97.110, I97.120, I97.710, I97.190, I97.790, I97.111, I97.121, Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: gik, control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Between 18 and 70 years of age

          -  Elective cardiac surgery with first time cardiopulmonary bypass

          -  Left ventricular ejection fraction(LVEF) ≥ 30%

          -  Informed agreement signed

        Exclusion Criteria:

          -  Previous cardiac surgery

          -  Emergent surgery

          -  Cardiac surgery without the use of cardiopulmonary bypass

          -  Diabetes mellitus

          -  Severe renal insufficiency

          -  Severe respiratory insufficiency

          -  Serious preoperative illness (sepsis, active infection or active malignancy requiring
             treatment)

          -  Pregnant woman or positive pregnancy test

          -  History of drug abuse

          -  Subject has a history of bleeding diathesis, coagulopathy, or refuses blood
             transfusion

          -  Enrollment in another clinical study

          -  Lack of informed consent
Clinical trial NCT00664521 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: atacicept, placebo matched to atacicept
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects

          -  Greater than and equal to (>=) 18 years of age at the time of Informed Consent

          -  Who have rheumatoid arthritis satisfying American College of Rheumatology (ACR)
             criteria with a disease history of at least 12 months

          -  Subjects must have active disease defined by DAS28 >3.2

          -  Subjects must have received previous treatment with rituximab and must be candidates
             for re-treatment with rituximab

          -  Female subjects of childbearing potential must be willing to avoid pregnancy by using
             an adequate method of contraception for 4 weeks before study day 1 (SD1), during the
             treatment period and for 12 months after the last dose of rituximab, and must have a
             negative urine pregnancy test at the screening visit and SD1

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Current neurological disease excluding migraine

          -  Inflammatory joint disease other than rheumatoid arthritis

          -  Any contraindication to rituximab as per national label

          -  Use of disease-modifying anti-rheumatic drugs (DMARDs; including methotrexate) for
             less than 3 months or change in dosing regimen within 28 days before SD1, or
             methotrexate dose regimen >25 mg/week

          -  Participation in any interventional clinical trial within 1 month before SD1 (or
             within 5 half-lives of the investigated compound before SD1, whichever is longer)

          -  Prednisone dose regimen >10 mg/day (or equivalent), or change in steroid dosing
             regimen within 28 days before SD1

          -  Active or latent tuberculosis within the year before screening or major infection
             requiring hospitalization or intravenous anti-infectives within 28 days before SD1

          -  Serum Immunoglobulin G (IgG) below 6 gram per liter (g/L)

          -  Known hypersensitivity to atacicept or to any of the components of the formulated
             atacicpet

          -  Known hypersensitivity to rituximab, to any of the components of the formulated
             rituximab or to murine proteins

          -  Breastfeeding or pregnancy

          -  Other protocol defined exclusion criteria could apply
Clinical trial NCT01417078 (phase 2, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: diazepam
SMILES: CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Eligibility criteria:

        Inclusion Criteria:

          -  Provide signed informed consent for study participation.

          -  General good health with no clinically significant unstable abnormalities.

          -  Diagnosis of epilepsy.

        Exclusion Criteria:

          -  Individuals receiving warfarin (Coumadin®) or dabigatran (Pradaxa®).

          -  Use of any investigational drug within 30 days.

          -  Blood or plasma donation within 30 days.

          -  Not willing or unable to tolerate blood draws.
Clinical trial NCT01369745 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: prednisolone, dipyridamole, prednisone, z102
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Meet the ACR / EULAR criteria for classification of RA

          -  Have moderate to severe RA, defined as involving a minimum (≥6 total swollen and ≥6
             total tender) of the 28 joints assessed

          -  Have screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score ≥4.5

          -  Have been on a stable dose of conventional DMARD therapy for at least 90 days without
             dosage adjustment or modification and should be able to maintain the same dose of
             conventional DMARD therapy during study participation (with or without glucocorticoid
             therapy

        Exclusion Criteria:

          -  Treatment-refractory patients are excluded

          -  Has active cardiovascular disease, unless well controlled by appropriate treatment for
             a minimum of 3 months prior to screening

          -  Is taking aspirin for reasons other than for cardiovascular prophylaxis or their total
             daily dose is greater than 325 mg

          -  Is currently taking steroids at a daily prednisone dose, or the equivalent, of >10 mg

          -  Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given
             at least 6 weeks prior to entering the study

          -  The need to continue the use of one or multiple NSAID's at the same time, or the use
             of acetaminophen on a chronic basis

          -  All opiate use is prohibited

          -  Use of any other medications or herbs used for the treatment of pain is prohibited

          -  Patients with a history of or currently active tuberculosis as per specific country
             guidelines are excluded

          -  Has uncontrolled diabetes mellitus as defined by a serum glucose >126 mg/dl

          -  Knowingly has HIV infection or hepatitis

          -  Has undergone administration of any investigational drug within 30 days of study
             initiation

          -  All biologic agents are excluded for 90 days prior to Screening and throughout the
             study.

          -  Has undergone administration of rituximab or any B-cell depleting investigational
             drugs within 6 months of study initiation

          -  Has had a history of alcohol or drug abuse within the past 2 years

          -  Has a history of hypersensitivity to glucocorticoids and/or dipyridamole
Clinical trial NCT00447967 (phase 2, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan, oxaliplatin, fluorouracil, leucovorin, oxaliplatin
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic gastric cancer.

          -  Measurable or evaluable disease.

          -  Measurable disease is defined as at least 1 unidimensionally measurable lesion ≥ 20 mm
             by conventional techniques or 1 bidimensionally measurable lesion ≥ 20 X 10 mm.
             Lesions that are smaller or uni- or bidimensionally unmeasurable are considered as
             evaluable disease.

          -  Previous adjuvant chemotherapy with Irinotecan, Oxaliplatin and/or 5-FU based regimen.
             Patients who relapse within the first 6 months after the completion of adjuvant
             treatment are not eligible for the study.

          -  Karnofsky performance status > 70%.

          -  Age ≥18 years.

          -  Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL), renal
             (Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥ 100,000/mm3) function.

          -  Patients must be able to understand the nature of this study and give written informed
             consent.

        Exclusion Criteria:

          -  Active infection

          -  History of serious cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  Previous radiotherapy within the last 4 weeks or > 25% of bone marrow.

          -  Patients with CNS metastases

          -  Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction.

          -  Malnutrition or loss of > 10% of body weight during the last month.

          -  Peripheral neuropathy ≥ grade 2

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Pregnant or lactating women.
Clinical trial NCT01720251 (phase 2, status: completed)
Conditions: allergic rhinitis, rhinoconjunctivitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: placebo, allert low dose, allert full dose
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  moderate to severe allergic rhinoconjunctivitis to birch pollen:

               1. Score of symptoms of the Rhinoconjunctivitis Symptom Score (RSS) ≥ 12 during the
                  two preceding birch pollen seasons

               2. Previous use of anti-allergy medications during the two preceding birch pollen
                  seasons

               3. Positive SPT to birch pollen extract

               4. Positive specific IgE CAP test for Bet v 1

        Exclusion Criteria:

          -  uncontrolled asthma, FEV1 < 80% of predicted

          -  previous SIT (specific immunotherapy) to birch pollen or any other SIT within 5 years

          -  clinical symptoms due to allergens other than birch pollen during the whole trial
             period

          -  history of anaphylaxis

          -  positive skin prick test to AllerT

          -  any other treatment or conditions which may increase the risk of the study for the
             subject or affect the efficacy assessments during the birch pollen season
Clinical trial NCT00697281 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: oc000459, oc000459, oc000459, oc000459, placebo
SMILES: CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged 18 to 50 years with a history of symptoms of grass pollen
             related allergic rhinitis within the previous two years.

          -  Females of childbearing potential (i.e. having had a menstrual period within two years
             prior to the date of screening) must practise two forms of contraception and must have
             a negative pregnancy test (blood or urine) at screening.

          -  Acceptable contraception includes the use of TWO of the following:

               -  oral contraception (i.e. the Pill);

               -  intrauterine device (an IUD or 'Coil');

               -  barrier contraception (i.e. condoms or diaphragm/cap);

               -  transdermal patch

        Exclusion Criteria:

          -  Medical conditions likely to affect the outcome of the study.

          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal
             perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal
             diseases as determined by the principal investigator or designee.

          -  Presence of any respiratory disease other than a history of mild stable asthma not
             requiring treatment and associated with normal lung function (defined as FEV1 ≥ 90%
             predicted for height and age).

          -  Immunotherapy treatment course in the past 28 days

          -  Use of inhaled or local corticosteroids in the past 28 days.
Clinical trial NCT00106002 (phase 2, status: completed)
Conditions: breast cancer, breast neoplasms, male, carcinoma, ductal
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Must have been diagnosed with either advanced or metastatic breast cancer.

          -  Chemotherapy has not been given for advanced or metastatic breast cancer.

          -  The diagnosis of advanced or metastatic breast cancer was made at least 12 months
             after chemotherapy was given after breast surgery.

          -  Able to carry out work of a light nature (for example, light housework, office work).

          -  Must be at least 18 years old.

        Exclusion Criteria:

          -  Have received prior bone marrow or peripheral stem cell transplantation.

          -  Have received prior chemotherapy for metastatic breast cancer.

          -  Are currently pregnant or breast-feeding.

          -  Have an active infection that your doctor decides will affect your safety.

          -  Are unable to take folic acid or vitamin B12.
Clinical trial NCT00223041 (phase 2/phase 3, status: terminated)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: fluvastatin
SMILES: CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
Reason stopped: 
    no possibilty to receive all plened patients for this study
  
Eligibility criteria:

        Inclusion Criteria:

          -  patients (18 - 65, inclusive)

          -  cadaver and living kidney transplantation (1. Ntx, 2. Ntx)

          -  LDL-cholesterol ≤ 130mg/dl (-3 Mo until start of Tx)

          -  Patients with a history of Myocard infarct: LDL-Cholesterol ≤ 110mg/dl

          -  Immunsuppression: Tacrolimus in combination with steroids or Mycophenolat Mofetil

          -  patients indulgence

        Exclusion Criteria:

          -  statin before the study

               -  LDL-Cholesterol >130mg/dl before transplantation

               -  Instabil Angina, Myocard infarct <6 months before transplantation

               -  symptomatic Hypothyreosis

               -  child bearing, lactating

               -  elavated liver encymes (> 2x elavated: AST, ALT, bilirubine, PCK)

               -  Fibrates are not allowed

               -  multiorgantransplantation
Clinical trial NCT01393132 (phase 2, status: completed)
Conditions: dry eye, sjogren's syndrome, graft vs. host disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121, M35.00, M35.01, M35.03, M35.0B, M35.02, M35.05, M35.08
Drugs: thymosin beta 4 eye drops, vehicle control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Schirmers of < 5 mm at 5 minutes

          -  TFBUT: less than 10 seconds

          -  Corneal staining of >3 of 15: conjunctival staining of >3 of 18

          -  Ocular Surface Disease Index of > 50

          -  Presumed best corrected vision of 20/60 or better

        Exclusion Criteria:

          -  Acute or inflammatory corneal disease

          -  Pregnancy or lactation

          -  Monocular status

          -  Punctal occlusion within 30 days

          -  Ocular surgery within 3 months

          -  Corneal thinning of >50%

          -  Active corneal infection

          -  History of ocular malignancy

          -  Retinal neovascularization

          -  Current use of topical cyclosporin A
Clinical trial NCT01136382 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 2
             that has required daily inhaled corticosteroid in the low dose range OR LTRA as
             monotherapy for at least 30 days prior to Visit 2.

          -  Has a morning clinic pre-bronchodilator FEV1 measured at least 6 hours after the last
             dose of inhaled short acting beta agonist of greater than or equal to 70% and less
             than or equal to 95% of predicted normal

          -  Demonstrated reversibility of FEV1 of ≥12% from pre short acting beta agonist level
             within 15 to 30 minutes after administration of a standard dose of short acting beta
             agonist OR has a documented reversibility of ≥ 12 % within 12 months prior to Visit 2.

        Exclusion Criteria:

          -  Has been hospitalized at least once or required emergency treatment (was seen in the
             emergency room or had an urgent care visit) more than once for an asthma-related
             condition during the 6 months prior to Visit 2

          -  Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal)
             for any reason within the 12 weeks prior to Visit 2